Literature DB >> 9847059

The supracostal percutaneous nephrostomy for treatment of staghorn and complex kidney stones.

D Golijanin1, R Katz, A Verstandig, T Sasson, E H Landau, S Meretyk.   

Abstract

From March 1995 to May 1997, 104 patients underwent 115 supracostal percutaneous nephrolithotomy (PCNL) procedures for the treatment of 102 complete staghorn calculi, 6 large semistaghorn calculi, 3 large upper-caliceal stones, and 4 significant volumes of residual stone fragments after SWL. Additional renal access was required mainly for complete staghorn stones (23 patients; 20%). Extracor poreal lithotripsy was performed in 30.4% of cases, and second-look PCNL was done in 15.6%. The stone-free rate was 87%, and the infection-free rate at 7 to 33 months was 88.5%. Among 115 supracostal PCNL procedures, complications were encountered in 10 (8.7%). These problems included four large pleural effusions that were drained by chest tube in three patients and by repeated thoracocentesis in one patient. Six patients developed significant atelectasis, which was treated by vigorous physiotherapy in five and flexible bronchoscopy in one. We conclude that the supracostal approach provides direct and optimal access to most staghorn calculi with an excellent stone-free rate. The advantages of this approach can be achieved with a slight and acceptable increase in morbidity.

Entities:  

Mesh:

Year:  1998        PMID: 9847059     DOI: 10.1089/end.1998.12.403

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  17 in total

Review 1.  Planning and Execution of Access for Percutaneous Renal Stone Removal in a Community Hospital Setting.

Authors:  Robert M Springer
Journal:  Semin Intervent Radiol       Date:  2015-09       Impact factor: 1.513

2.  Flank bulge following supracostal percutaneous nephrolithotomy: A report of 2 cases.

Authors:  Andrea G Lantz; Kenneth T Pace; R John D'A Honey
Journal:  Can Urol Assoc J       Date:  2013 Jul-Aug       Impact factor: 1.862

Review 3.  Fluoroscopy guided percutaneous renal access in prone position.

Authors:  Gyanendra R Sharma; Pankaj N Maheshwari; Anshu G Sharma; Reeta P Maheshwari; Ritwik S Heda; Sakshi P Maheshwari
Journal:  World J Clin Cases       Date:  2015-03-16       Impact factor: 1.337

4.  Prospective randomized comparison between superior calyceal access versus inferior calyceal access in PCNL for inferior calyceal stones with or without pelvic stones.

Authors:  Vishwajeet Singh; Yogesh Garg; Kuldeep Sharma; Rahul Janak Sinha; Saurabh Gupta
Journal:  Urolithiasis       Date:  2015-07-19       Impact factor: 3.436

5.  Nephrostolithotomy.

Authors:  Darryl A Zuckerman; Alena Desai
Journal:  Semin Intervent Radiol       Date:  2011-12       Impact factor: 1.513

6.  Supracostal Punctures for PCNL: Factors that Predict Safety, Success and Stone Free Rate in Stag Horn and Non-Stag Horn Stones: A Single Centre Experience and Review of Literature.

Authors:  Hariharasudhan Sekar; Sriram Krishnamoorthy; Natarajan Kumaresan; Venkat Ramanan
Journal:  J Clin Diagn Res       Date:  2016-09-01

7.  Supracostal Approach for PCNL: Is 10th and 11th Intercostal Space Safe According to Clavien Classification System?

Authors:  Cengiz Kara; Tansu Değirmenci; Zafer Kozacioglu; Bulent Gunlusoy; Omer Koras; Suleyman Minareci
Journal:  Int Surg       Date:  2014 Nov-Dec

8.  The feasibility of regional anesthesia in the percutaneous nephrolithotomy with supracostal approach and its comparison with general anesthesia.

Authors:  M K Moslemi; S H Mousavi-Bahar; M Abedinzadeh
Journal:  Urolithiasis       Date:  2012-12-21       Impact factor: 3.436

9.  Perioperative Respiratory Compromise in Patients Undergoing PCNL-A Case Series.

Authors:  Ponnambala Namasivayam S
Journal:  J Clin Diagn Res       Date:  2013-10-05

10.  Supracostal access for percutaneous nephrolithotomy: less morbid, more effective.

Authors:  Sudhir Sukumar; Balagopal Nair; Kumar P Ginil; K V Sanjeevan; Bhat H Sanjay
Journal:  Int Urol Nephrol       Date:  2008       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.